PURPOSE: This study investigated the diagnostic accuracy of the serum biomarkers osteopontin and mesothelin in discriminating mesothelioma patients from those with other, benign conditions and whether levels of the biomarkers differed in subjects who had inhaled naturally occurring asbestos compared with a non-exposed control group. METHODS: This cross-sectional study studied 24 subjects with mesothelioma, 279 subjects with pleural plaques, 123 "healthy exposed," and 120 control subjects. The Kruskal-Wallis test was performed to compare mesothelin and osteopontin levels of the groups, and receiver operating characteristics curves were generated to determine diagnostic yields of both biomarkers. Multiple linear regression analyses were used to identify associated covariates with osteopontin and mesothelin levels. RESULTS: Serum osteopontin and mesothelin levels were higher in mesothelioma than in benign asbestos-related diseases and healthy exposed subjects. Both biomarker levels were independently associated with mesothelioma, age and smoking pack years. Mesothelin levels were also associated with body mass index. The sensitivity and specificity of osteopontin in distinguishing mesothelioma from the three other groups were 75 and 86 %, respectively; those of mesothelin were 58 and 83 %, respectively. The sensitivity and specificity to discriminate mesothelioma from pleural plaques and healthy subjects were 93 and 73 %, respectively, if osteopontin and mesothelin levels were higher than their optimal cut off levels. CONCLUSIONS: The combination of serum osteopontin and mesothelin levels can help to distinguish mesothelioma from benign asbestos-related diseases and asbestos-exposed subjects.
PURPOSE: This study investigated the diagnostic accuracy of the serum biomarkers osteopontin and mesothelin in discriminating mesotheliomapatients from those with other, benign conditions and whether levels of the biomarkers differed in subjects who had inhaled naturally occurring asbestos compared with a non-exposed control group. METHODS: This cross-sectional study studied 24 subjects with mesothelioma, 279 subjects with pleural plaques, 123 "healthy exposed," and 120 control subjects. The Kruskal-Wallis test was performed to compare mesothelin and osteopontin levels of the groups, and receiver operating characteristics curves were generated to determine diagnostic yields of both biomarkers. Multiple linear regression analyses were used to identify associated covariates with osteopontin and mesothelin levels. RESULTS: Serum osteopontin and mesothelin levels were higher in mesothelioma than in benign asbestos-related diseases and healthy exposed subjects. Both biomarker levels were independently associated with mesothelioma, age and smoking pack years. Mesothelin levels were also associated with body mass index. The sensitivity and specificity of osteopontin in distinguishing mesothelioma from the three other groups were 75 and 86 %, respectively; those of mesothelin were 58 and 83 %, respectively. The sensitivity and specificity to discriminate mesothelioma from pleural plaques and healthy subjects were 93 and 73 %, respectively, if osteopontin and mesothelin levels were higher than their optimal cut off levels. CONCLUSIONS: The combination of serum osteopontin and mesothelin levels can help to distinguish mesothelioma from benign asbestos-related diseases and asbestos-exposed subjects.
Authors: Heather L Beyer; Ryan D Geschwindt; Curtis L Glover; Ly Tran; Ingegerd Hellstrom; Karl-Erik Hellstrom; M Craig Miller; Thorsten Verch; W Jeffrey Allard; Harvey I Pass; Niranjan Y Sardesai Journal: Clin Chem Date: 2007-02-08 Impact factor: 8.327
Authors: Kevin Hollevoet; Dirk Bernard; Frank De Geeter; Natascha Walgraeve; Anja Van den Eeckhaut; Raymond Vanholder; Christophe Van de Wiele; Veronique Stove; Jan P van Meerbeeck; Joris R Delanghe Journal: Clin Chem Date: 2009-04-30 Impact factor: 8.327
Authors: Arnaud Scherpereel; Bogdan Grigoriu; Massimo Conti; Thomas Gey; Marc Grégoire; Marie-Christine Copin; Patrick Devos; Bachar Chahine; Henri Porte; Philippe Lassalle Journal: Am J Respir Crit Care Med Date: 2006-02-02 Impact factor: 21.405
Authors: Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom Journal: Lancet Date: 2003-11-15 Impact factor: 79.321
Authors: Clementina Mesaros; Andrew J Worth; Nathaniel W Snyder; Melpo Christofidou-Solomidou; Anil Vachani; Steven M Albelda; Ian A Blair Journal: Bioanalysis Date: 2015 Impact factor: 2.681